PPARG and obesity due to melanocortin 4 receptor deficiency: PPARγ antagonists have been shown to have anti-obesity and anti-diabetic activity10, 11, 12, 13, suggesting that the inhibition of PPARγ activity may be beneficial to prevent obesity, steatosis and other metabolic disorders.